A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2012

At a glance

  • Drugs Retigabine (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 10 Jan 2012 Additional lead trial investigator (David Lineberry) identified as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov record.
    • 13 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top